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MaThe development of secondary mitral regurgitation (MR) due to left ventricular dysfunction, also known as functional
MR, is strongly associated with a poor prognosis in patients with heart failure. The mechanisms underlying secondary MR
are multifactorial; accurate imaging assessment of secondary MR may be challenging and nuanced; and the appropriate
roles of medical, surgical, and interventional therapies for management of secondary MR are controversial and evolving.
In this review, the pathophysiology, evaluation, and prognosis of secondary MR in patients with heart failure are dis-
cussed, and we evaluate in detail the evidence for the various therapeutic approaches for secondary MR, including
guideline-directed medication for left ventricular dysfunction, cardiac resynchronization therapy and revascularization
when appropriate, and mitral valve surgery and transcatheter interventions. The role of a multidisciplinary heart team in
determining the optimal management strategy for secondary MR is also discussed. (J Am Coll Cardiol 2015;65:1231–48)
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of w1.7%, increasing with age to w9.3% in those >75
years of age (1). MR is classiﬁed as primary (also
known as organic) when principally due to a struc-
tural or degenerative abnormality of the mitral valve
(MV), whether of the leaﬂets, chordae tendineae,
papillary muscles, or mitral annulus. Secondary
(also known as functional) MR occurs in the absence
of organic MV disease, usually from left ventricular
(LV) dysfunction. It is more common than primary
MR (2), is associated with a worse prognosis (com-
pounded by the underlying cardiomyopathy), and
(in contrast to primary MR) the beneﬁts of MV surgery
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PATHOPHYSIOLOGY OF SECONDARY MR
The MV consists of 2 leaﬂets (anterior and posterior)
sitting within the annulus (Figure 1). The posterior
mitral leaﬂet originates from the left atrial (LA)
endocardium. A subvalvular apparatus, comprising 2
papillary muscles (anterolateral and posteromedial)
arising from the LV myocardium and the chordae
tendineae, supports the leaﬂets. LV dilation due to
ischemic or nonischemic cardiomyopathy secondarily
impairs leaﬂet coaptation of a structurally normal
MV, resulting in secondary MR. Speciﬁcally, LVital Baylor Plano, Baylor HealthCare System, Dallas,
arch Foundation, New York, New York. Dr. Asgar has
executive committee of the Partner Trial (Edwards
rial (Abbott Vascular, uncompensated). Dr. Stone has
tigator of the Coapt Trial (Abbott Vascular, uncom-
ntin Fuster.
r. Valentin Fuster.
y 16, 2015, accepted February 3, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
ACEI = angiotensin-converting
enzyme inhibitor(s)
CRT = cardiac
resynchronization therapy
EROA = effective regurgitant
oriﬁce area
GDMT = guideline-directed
medical therapy
HF = heart failure
LBBB = left bundle branch
block
LVEF = left ventricular
ejection fraction
MDCT = multidetector
computed tomography
MR = mitral regurgitation
MV = mitral valve
NYHA = New York Heart
Association
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1232dysfunction and remodeling lead to apical
and lateral papillary muscle displacement,
resulting in leaﬂet tethering (3), dilation and
ﬂattening of the mitral annulus, and reduced
valve closing forces. Because these changes
are dependent on loading conditions and the
phase of the cardiac cycle, secondary MR is
dynamic in nature.
Papillary muscle displacement occurs as a
result of global LV enlargement or focal
myocardial scarring, and can affect 1 or
both papillary muscles, causing posteriorly
directed or central MR (Figure 2) (4). With
chronic MR, the mitral leaﬂet area may in-
crease up to 35% over time, an adaptive
response that minimizes the degree of
regurgitation; insufﬁcient leaﬂet remodeling
may contribute to severe MR (5,6). However,
even in patients with increased mitral leaﬂet
area, papillary muscle displacement with
subsequent decreased coaptation length maystill result in signiﬁcant MR (6).
The normal saddle-shape of the annulus is impor-
tant for maintaining normal leaﬂet stress (7). Loss
of this shape and annular ﬂattening with LV remodel-
ing result in increased leaﬂet stress with secondary
MR. In addition, LV systolic dysfunction reduces
the strength of MV closing, which opposes the leaﬂet
tethering forces created by papillary muscle dis-
placement. These pathological changes culminate in
failure of leaﬂet coaptation and decreased valvular
closing forces due to LV dysfunction, resulting in
MR. The Carpentier classiﬁcation, commonly used by
surgeons to describe MV pathology, categorizes MR
using a mechanistic and functional approach to the
mitral leaﬂets (8). Secondary MR is most commonly
Carpentier type IIIB, and occasionally type I.
ISCHEMIC VERSUS NONISCHEMIC MR. MR can be
further classiﬁed as either ischemic or nonischemic.
In ischemic MR (the more frequent etiology), LV
remodeling after myocardial infarction (MI) results
in papillary muscle displacement, causing systolic
tenting of the MV. Global left ventricular ejection
fraction (LVEF) does not have to be reduced; regional
wall motion abnormalities with remodeling may
result in sufﬁcient MV tethering to cause severe MR,
despite preserved LVEF (9). Symmetric or asymmetric
leaﬂet tethering may occur. Symmetric tethering
is associated with substantial systolic dysfunction,
global remodeling, and increased LV sphericity
with a central regurgitant jet. Asymmetric tethering
most frequently results from localized remodeling
affecting the posterior papillarymuscle, with posterior
tenting of both leaﬂets (most pronounced at themedialor P3 portion of the posterior leaﬂet) causing a
posteriorly directed asymmetric regurgitant jet (Car-
pentier Type IIIB) (10).Mitral annular dilation typically
occurs late in the pathophysiology of secondary MR,
and is often asymmetric, with greater involvement
of the posterior annulus (11). Papillary muscle in-
farction is rarely the cause of secondary MR (12).
Nonischemic MR, most commonly due to long-
standing hypertension or idiopathic dilated car-
diomyopathy, is characterized by global LV dilation
with increased sphericity and (typically) a centrally
located regurgitant jet. Symmetric mitral annular
dilation is greatest in the septal-lateral direction, and
correlates with the severity of LV dysfunction (13).
MR DUE TO ATRIAL FIBRILLATION. An additional,
although relatively infrequent, cause of severe sec-
ondary MR is isolated LA enlargement, with or with-
out atrial ﬁbrillation, resulting in a dilated mitral
annulus and reduced leaﬂet coaptation (without
tenting or prolapse), with normal LV function and
mitral leaﬂets (Carpentier Type I) (14). In patients
with atrial ﬁbrillation, improvement in MR severity
may occur with restoration of sinus rhythm, sug-
gesting a causal relationship (14).
PROGNOSTIC IMPLICATIONS OF SECONDARY MR
A strong association between secondary MR severity
and both all-cause mortality and heart failure (HF)
hospitalizations has been reported. Among 303 pa-
tients with a completed Q-wave MI, any ischemic MR
was detected by echocardiography in 194 patients
(64.0%) and was a powerful, independent correlate
of long-term all-cause mortality (relative risk: 1.88
[95% conﬁdence interval (CI): 1.23 to 2.86], p ¼ 0.003)
(15). In a study from the Duke Cardiovascular Data-
bank, qualitatively assessed 3þ to 4þ MR on left
ventriculography was present in 29.8% of 2,057 HF
patients with an LVEF <40% and was an independent
predictor of 5-year mortality (adjusted hazard ratio
[HR]: 1.23 [95% CI: 1.13 to 1.34]) (16). Among 1,256
patients with dilated cardiomyopathy at the Mayo
Clinic, quantitatively assessed severe secondary MR
(deﬁned as an effective regurgitant oriﬁce area
[EROA] >0.2 cm2, a regurgitant volume >30 ml, or a
vena contracta width >0.4 cm) was present in 24% of
patients, and was an independent predictor of death
or HF hospitalization at median 2.5-year follow-up
(adjusted HR: 1.5 [95% CI: 1.2 to 1.9]), independent
of LVEF (17). This relationship was present separately
for death and HF hospitalizations, and in patients
with ischemic and nonischemic MR (Figure 3). Sec-
ondary MR is a powerful predictor of death or trans-
plant, even with less severe HF (18). However,
FIGURE 1 Mitral Valve Anatomy
The diagram illustrates the valve and supporting structures.
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1233although secondary MR is widely accepted to predict
a poor prognosis in patients with primary LV dys-
function and HF, whether this relationship is causal
and whether reducing MR improves patient prognosis
remain unknown.
EVALUATION OF SECONDARY MR
Comprehensive evaluation of the patient with HF
and secondary MR requires a detailed medical history
and physical examination, with laboratory, electro-
cardiographic, and echocardiographic assessment.
Most important is an accurate appraisal of the func-
tional limitations attributable to HF, the MV anatomy
and severity of MR, and evaluation of the left and
right heart circulation, including measurement of
chamber size and cardiac pressures. By integrating
these ﬁndings, secondary MR can be categorized into
4 stages that deﬁne prognosis and guide therapy:
1) at risk of secondary MR; 2) progressive secondary
MR; 3) asymptomatic severe secondary MR; and 4)
symptomatic severe secondary MR (Table 1) (19).
ECHOCARDIOGRAPHY. The cornerstone of diag-
nostic evaluation of MR is echocardiography, with
transesophageal and transthoracic echocardiogra-
phy playing complementary roles. Transesophageal
echocardiography most often accurately identiﬁes
the underlying cause and mechanism of MR, whether
primary or secondary. A mixed etiology is not un-
common (e.g., secondary MR with leaﬂet thickening
or mitral annular calciﬁcation). Transesophageal
echocardiographic measurements of leaﬂet length
and angles (particularly the posterolateral angle,
signifying posterior leaﬂet tethering), coaptationdistance and length, and tenting area are useful
in evaluating the suitability of secondary MR for
various interventional options. Conversely, because
LV unloading may lessen regurgitation, quantiﬁca-
tion of MR severity is most accurately assessed in
the awake patient by transthoracic echocardiography,
thereby avoiding the vasodilatory effects of seda-
tion, hypovolemia, and/or anesthesia with trans-
esophageal echocardiography. Echocardiography is
also indispensable for determining LV volumes,
function, and sphericity; for assessing pulmonary
artery pressures and right ventricular function and
quantifying tricuspid regurgitation; for assessing the
anatomic likelihood for successful MV repair or
transcatheter approaches; for guiding surgical and
transcatheter repair procedures; and for appraising
the durability and functional effect of MV therapies
through serial assessments over time.
The echocardiographic degree of MR, evaluated by
integrating qualitative and quantitative assessments,
is classiﬁed as mild, moderate, or severe (20). Quali-
tative ﬁndings include MV morphology and color ﬂow
and continuous wave signals of the MR jet. Semi-
quantitative insights into MR severity are provided
by pulmonary vein ﬂow and mitral inﬂow patterns.
Quantitative measures include EROA, regurgitant
volume, and regurgitant fraction. Enlarged LA and LV
chamber size and increased pulmonary artery pres-
sures provide supportive data for severe MR.
Conventional 2-dimensional (2D) assessment for
MR quantiﬁcation relies on measurement of the MR
jet core at its vena contracta or proximal convergence
zone using methods that assume circular oriﬁce ge-
ometry. MR severity may, therefore, be signiﬁcantly
underestimated when the oriﬁce is elliptical (as
is typical in secondary MR) (4), a situation that is
compounded if multiple jets are present. Three-
dimensional (3D) echocardiography overcomes this
limitation by permitting direct planimetry of the
vena contracta, regardless of oriﬁce shape or number
of jets (21). Conversely, both 2D and 3D color ﬂow
Doppler tend to overestimate the oriﬁce area because
of their inability to resolve the high velocity jet core
due to aliasing and blooming artifacts. Secondary
MR severity also varies during the cardiac cycle, and
can peak in early or late systole, further complicating
evaluation, which is traditionally done in midsystole.
No single parameter is sufﬁcient to quantify the
degree of MR, and multimodality assessment using
both 2D and 3D echocardiography is optimal (22).
Although somewhat controversial, outcomes
studies suggest that lesser absolute quantitative
degrees of regurgitation in secondary MR may have
the same or greater effect on mortality than in
FIGURE 2 Secondary MR Due to Left Ventricular Dilation
(A) A representative echocardiogram and diagram of ischemic MR, with a posteriorly directed jet. (B) A representative echocardiogram and
diagram of MR due to idiopathic dilated cardiomyopathy, with a central jet. Note the lateral displacement of the papillary muscles (arrows).
Apical displacement is also typically present, although less well demonstrated in these views. LVOT ¼ left ventricular outﬂow tract;
MR ¼ mitral regurgitation; TEE ¼ transesophageal echocardiography.
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1234primary MR (15,20). Whereas severe primary MR is
usually deﬁned as an EROA of $40 mm2 and a
regurgitant volume of $60 ml, Sarano et al. (15) pro-
posed and the most recent U.S. and European valve
guidelines have accepted EROA $20 mm2 and regur-
gitant volume $30 ml as consistent with severe sec-
ondary MR (19,23) (Table 2). However, the amount of
MR (assessed by either EROA or regurgitant volume)
resulting in loss of >50% of total stroke volume (i.e.,
the regurgitant volume) depends on the LV end-
diastolic volume and LVEF (24). This likely explains
why some studies show an adverse prognostic effect
of lesser EROA values, whereas others do not.
Exercise echocardiography may be useful when
symptoms appear disproportionate to resting MR
severity (25). Exercise results in greater pre-load
and afterload, a more spherical ventricle, increased
coaptation distance, and systolic expansion of themitral annulus. Such changes can occur in the
absence of ischemia (26) and may result in acute
pulmonary edema (27). Exercise-induced severe MR
may identify patients at heightened risk for death or
HF hospitalization (28). Quantitatively, an exercise-
induced EROA increase of $13 mm2 has been as-
sociated with increased morbidity and mortality,
although measuring EROA during or immediately
after exercise is technically challenging due to
tachycardia and tachypnea (29). Exercise echocardi-
ography may also demonstrate increasing pulmonary
artery pressures and lack of LV contractile reserve,
ﬁndings associated with LV dysfunction and poor
prognosis after MV surgery (30,31). Exercise may also
induce greater LV dyssynchrony with increased
MR, which might improve with cardiac resynchroni-
zation therapy (CRT) (see later discussion). However,
the predictive value of exercise echocardiography is
FIGURE 3 Prognosis of Quantitatively Determined Secondary Mitral Regurgitation in Patients With
Ischemic and Nonischemic Cardiomyopathy
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(Top) Freedom from death or heart failure (HF) hospitalization in 1,256 patients according to the degree of functional mitral regurgitation
(FMR). (Bottom) Freedom from death according to the degree of FMR in patients with ischemic (lower left) and nonischemic (lower right)
cardiomyopathy. Adapted with permission from Rossi et al. (17). HR ¼ hazard ratio.
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1235imperfect, given the technical issues of measuring
key parameters at or just after peak exercise;
confounding interpretations due to concomitant
ischemia and/or patient deconditioning (with limited
exercise capacity); and the potential for LV remodel-
ing with changing loading conditions after MV repair
in some patients. Larger studies are required to
determine the role of exercise echocardiography in
evaluation of the patient with secondary MR.
Echocardiography is also useful in determining the
likelihood of successful MV repair by either surgery or
transcatheter procedures (e.g., the MitraClip, Abbott
Vascular, Menlo Park, California) in patients with
secondary MR. In patients with secondary MR
undergoing surgery, successful repair is less likely
in the presence of: 1) MV deformation (coaptation
distance $1 cm, tenting area >2.5 to 3 cm2, and/or
complex jets originating centrally and postero-
medially, posterolateral angle >45 [high poste-
rior leaﬂet tethering]); 2) global LV remodeling(LV end-diastolic dimension >65 mm, end-systolic
dimension >51 mm, or systolic sphericity index
>0.7); and 3) local LV remodeling (interpapillary
muscle distance >20 mm, posterior papillary-ﬁbrosa
distance >40 mm, or lateral wall motion abnormal-
ity) (32). In a series of 300 patients with severe MR
undergoing MitraClip (68% of whom had secondary
MR), failure to achieve #2þ MR occurred in 31 pa-
tients (10.3%). By multivariable analysis, predictors
of failed MitraClip included greater EROA (odds
ratio [OR]: 1.21 per 10 mm2 increase, p ¼ 0.005) and
baseline transmitral pressure gradient $4 mm2 (OR:
1.26, p ¼ 0.03). Success rates were similar with pri-
mary and secondary MR (33). Of note, due to the
double MV oriﬁce and artifacts from the clip(s),
quantifying MR severity after the MitraClip with
echocardiography can be challenging.
NONECHOCARDIOGRAPHIC IMAGING TECHNIQUES.
Cardiac magnetic resonance (CMR) imaging and
TABLE 1 Stages of Secondary (Functional) MR
Grade Valve Anatomy Valve Hemodynamics* Cardiac Structure and Function Symptoms
A: At risk of MR  Normal valve leaﬂets,
chords, and annulus in a
patient with coronary
disease or cardiomyopathy
 No MR jet or small central
jet area <20% LA on
Doppler
 Small vena contracta
<0.30 cm
 Normal or mildly dilated
LV size with ﬁxed
(infarction) or inducible
(ischemia) regional wall
motion abnormalities
 Primary myocardial disease
with LV dilation and sys-
tolic dysfunction
 Symptoms due to coro-
nary ischemia or HF may
be present that respond
to revascularization and
appropriate medical
therapy
B: Progressive MR  Regional wall motion
abnormalities with mild
tethering of mitral leaﬂet
 Annular dilation with mild
loss of central coaptation
of the mitral leaﬂets
 EROA <0.20 cm2
 Regurgitant volume
<30 ml
 Regurgitant fraction <50%
 Regional wall motion
abnormalities with reduced
LV systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coro-
nary ischemia or HF may
be present that respond
to revascularization and
appropriate medical
therapy
C: Asymptomatic
severe MR
 Regional wall motion
abnormalities and/or LV
dilation with severe teth-
ering of mitral leaﬂet
 Annular dilation with
severe loss of central
coaptation of the mitral
leaﬂets
 EROA $0.20 cm2
 Regurgitant volume
$30 ml
 Regurgitant fraction $50%
 Regional wall motion
abnormalities with reduced
LV systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coro-
nary ischemia or HF may
be present that respond
to revascularization and
appropriate medical
therapy
D: Symptomatic
severe MR
 Regional wall motion
abnormalities and/or LV
dilation with severe teth-
ering of mitral leaﬂet
 Annular dilation with
severe loss of central
coaptation of the mitral
leaﬂets
 EROA $0.20 cm2
 Regurgitant volume
$30 ml
 Regurgitant fraction $50%
 Regional wall motion
abnormalities with reduced
LV systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 HF symptoms due to MR
persist even after revas-
cularization and optimi-
zation of medical therapy
 Decreased exercise
tolerance
 Exertional dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity; not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or severe
depends on data quality and integration of these parameters in conjunction with other clinical evidence. Adapted with permission from Nishimura et al. (19).
EROA ¼ effective regurgitant oriﬁce area; HF ¼ heart failure; LA ¼ left atrium; LV ¼ left ventricular; MR ¼ mitral regurgitation.
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1236multidetector row computed tomography (MDCT)
can provide complementary information to echocar-
diography in patients with MR. CMR, in particular,
is highly accurate for quantifying the degree of MR
(34). Given its high spatial resolution, MDCT can
accurately depict MV structure and morphology
(35), and is useful in demonstrating the relationship
of the MV complex to other cardiac structures
(e.g., the relationship of the coronary sinus to the
mitral annulus and circumﬂex coronary artery) (36).
Both techniques provide true volumetric measures of
chamber dimensions and function and also assess
myocardial ﬁbrosis (scar). In the future, CMR and
MDCT will likely be increasingly used in the evalua-
tion of patients with HF and MR.
THERAPEUTIC CONSIDERATIONS FOR
SECONDARY MR
The goals of therapy in patients with secondary MR
are to improve symptoms and quality of life, reduce
HF hospitalizations, and potentially improve sur-
vival. To date, the most effective therapies for
secondary MR are aimed at the underlying LV
dysfunction, including guideline-directed medical
therapy (GDMT) for HF and biventricular pacing(CRT) when appropriate. Coronary revascularization
may also be considered in patients with extensive
ischemia and preserved myocardial viability, al-
though it rarely markedly reduces or eliminates sec-
ondary MR. The role of surgical and transcatheter
MV repair or replacement to interrupt the progres-
sive cycle of LV volume overload / LV dilation /
secondary MR/ increasing LV volume overload and
dilation / increasing MR is less well established,
although some patients may symptomatically beneﬁt.
Finally, in patients with severe HF and secondary
MR refractory to standard therapies, consideration
should be given to mechanical LV assist devices and
heart transplantation.
MEDICAL THERAPY FOR SECONDARY MR
GDMT for HF is ﬁrst-line treatment for patients with
secondary MR (19), although the morbidity and mor-
tality of patients with LV dysfunction and secondary
MR remain high. Among 404 secondary MR patients
treated with GDMT, 4-year cardiac mortality occurred
in 43% and 45% with moderate and severe MR,
respectively, compared with only 6% with mild MR
(p ¼ 0.003) (37). Moderate or severe MR was also an
independent predictor of new onset HF in patients
TABLE 2 Quantitative Echocardiographic Criteria for Severe MR in
Primary and Secondary Disease of the Mitral Valve
Primary
(Organic) MR
Secondary
(Functional) MR
EROA $0.4 cm2 $0.2 cm2*
Regurgitant volume $60 ml $30 ml
Regurgitant fraction $50% $50%
Vena contracta $0.7 cm —
Jet area Central jet >40% LA
or holosystolic eccentric jet
—
*Measurement of the proximal isovelocity surface area by 2-dimensional transthoracic echocar-
diography in secondary MR underestimates the true EROA due to the crescent shape of the
proximal convergence. Adapted with permission from Nishimura et al. (19).
Abbreviations as in Table 1.
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1237with ischemic LV dysfunction (relative risk: 3.2
[95% CI: 1.9 to 5.2], p ¼ 0.0001).
Beta-blockers and angiotensin-converting enzyme
inhibitors (ACEIs) are recommended for all patients
with LV dysfunction and secondary MR. By reversing
LV remodeling, maximal GDMT may secondarily
reduce severe MR. Surprisingly, however, few studies
have examined the effect of medical therapies on
secondary MR. In several small, nonrandomized
studies, carvedilol in patients with HF and secondary
MR was associated with improved LV systolic func-
tion with reduced MR severity lasting 6 to 12 months
(38,39). In a randomized trial of 59 patients with
HF and severe dilated cardiomyopathy, treatment
with carvedilol versus placebo resulted in reduced
LV mass and sphericity, with improved systolic
function. The severity of MR, assessed by the ratio of
MR jet area/LA area, increased during follow-up in
the placebo group, but decreased in the carvedilol
group (p ¼ 0.04) (40). In the largest randomized trial,
among 138 patients with dilated cardiomyopathy on
stable doses of digoxin, diuretic agents, and ACEI
assigned to metoprolol (titrated to 50 mg, 3 times
a day) or placebo, the metoprolol group had greater
6-month reductions in LV end-diastolic and end-
systolic volumes, which correlated with improved
secondary MR (41). However, MR improved in only
w42% of metoprolol-treated patients (vs. 20% of
control-group patients), and there were no signiﬁcant
differences in symptoms or rates of cardiac read-
mission or death during follow-up.
Less has been reported on the ability of ACEI and
other agents to reduce secondary MR. In a small study
of 19 patients with severe dilated cardiomyopathy
(mean LVEF w20%) and 3þ/4þ MR on stable doses
of digoxin, diuretic agents, lisinopril, and isosorbide
dinitrate, lisinopril was up-titrated from a mean 16
to 55 mg/day, and isosorbide from 30 to 286 mg/day.
At 12-month follow-up, MR had decreased to grade
0/1þ in 8 patients (42%; the MR responders), and
remained 3þ/4þ in the remainder. LVEF improved
in both groups, but to a greater degree in the MR
responders, and the LV end-diastolic dimension
decreased in the responders, but increased in the
nonresponders (42).
CRT FOR SECONDARY MR
CRT is a well-established treatment for HF in selected
patients with LV dyssynchrony. CRT is a Class I
recommendation for patients in sinus rhythm with
New York Heart Association (NYHA) functional class
II to IV symptoms on GDMT with LVEF #35%,
left bundle branch block (LBBB), and QRS duration$150 ms. CRT may also be useful in patients with
LVEF #35%, with sinus rhythm and non-LBBB pattern
with QRS duration $150 ms, and in those with LBBB
and QRS duration 120 to 149 ms (Class IIa indications)
(43). Randomized trials demonstrated improvements
in both survival and HF rehospitalization rates in
patients treated with CRT with or without a deﬁbril-
lator (44), along with reductions in LV end-diastolic
and end-systolic dimensions and improved LVEF.
The effect of CRT on secondary MR is inconsistent,
although most studies show a reduction in overall
MR severity with restoration of synchronous ven-
tricular contraction and LV remodeling. In the
sham-controlled MIRACLE (Multicenter InSync Ran-
domized Clinical Evaluation) trial of 450 NYHA
functional class III/IV HF patients with LVEF #35%
and QRS duration $130 ms, CRT resulted in marked
reductions in LV end-diastolic and end-systolic vol-
umes, improved LVEF, and sustained reductions in
MR (assessed by the relative size of the mitral jet area
in the LA) (45). Similarly, in a sham-controlled trial of
610 NYHA functional class I/II HF patients with
LVEF #40% and QRS duration $120 ms, CRT resulted
in sustained reductions in MR severity at 3 and
6 months, with parallel improvements in LV di-
mensions (46). In addition to reducing LV dimen-
sions and restoring papillary muscle geometry, CRT
can acutely reduce secondary MR by increasing the
rise in the transmitral pressure gradient and altering
the balance between the closing and tethering forces
on the MV (47). In a study of 63 patients with HF and
moderate/severe MR, 43% experienced immediate
improvement in MR by $1 grade, as assessed by vena
contracta width after CRT, and an additional 20%
demonstrated late improvement at 6 months (48).
Unfortunately, severe secondary MR improves in
no more than one-half of patients after CRT, although
such improvement identiﬁes a cohort with an
improved prognosis. In a study of 85 HF patients with
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12383þ/4þ secondary MR, MR grade at 6 months was
reduced after CRT in 42 (49%). Two-year survival was
92% in MR responders versus 67% in nonresponders
(p < 0.001) (49). In a recent study of 240 HF patients
(114 with $2þ secondary MR), MR severity at 6
months decreased in 48 (42%), remained stable in 42
(37%), and worsened in 24 (21%). The 4-year adverse
event rates were strongly predicted by the presence
of at least moderate MR after (but not before) CRT
(50). It is not clear whether CRT improves the prog-
nosis of secondary MR independent of its effects
on LV dysfunction or whether MR responders after
CRT represent a cohort with a more favorable prog-
nosis. In this regard, CRT-treated HF patients with
versus without secondary MR have a worse prog-
nosis; EROA $0.20 cm2 predicts poor response to
CRT, increased mortality, and HF rehospitalizations
(51). Nonetheless, if otherwise indicated, CRT is a
reasonable front-line therapy for secondary MR in HF
patients (along with GDMT), and should be performed
prior to MV surgery or transcatheter intervention.
SURGERY FOR SECONDARY MR
Surgical options for secondary MR include surgical
MV repair and replacement, mechanical LV assist
devices, and orthotopic heart transplantation. Al-
though secondary MR can be acutely corrected by
MV surgery, the surgery has never clearly been
demonstrated to alter the natural history of the pri-
mary disease (dilated cardiomyopathy) or improve
survival (52–55). Moreover, whether the response to
surgery is different in secondary MR due to ischemic
versus nonischemic cardiomyopathy has not been
established.
MV ANNULOPLASTY. MV reconstruction with pres-
ervation of annular-chordal-papillary muscle conti-
nuity results in maintenance of LV systolic function
with reduced LV volumes and end-systolic wall
stress. The most commonly performed surgical tech-
nique is MV annuloplasty, which addresses only 1
component of secondary MR: mitral annular dilation.
“Undersizing” the annuloplasty ring by matching
the ring size to the anterior leaﬂet overcorrects the
annular dilation, minimizing the effects of leaﬂet
tethering (56). Annular dilation is most pronounced
in the septal lateral dimension, and various ring
designs have been used to overcorrect in this
dimension, thus restoring leaﬂet coaptation.
The risk-beneﬁt ratio for MV annuloplasty in pa-
tients with secondary MR not requiring coronary
artery bypass grafting (CABG) compared with med-
ical therapy alone is uncertain. Although initial re-
sults of undersized annuloplasty were encouraging,long-term follow-up failed to demonstrate a survival
beneﬁt. Isolated MV annuloplasty was performed in
126 of 419 patients with severe secondary MR and
LVEF #30% at the University of Michigan (52). At a
mean 5.5-year follow-up, the propensity-adjusted
freedom from death, LV assist device, or United
Network for Organ Sharing-1 transplant listing
occurred in 41% of patients treated with medical
therapy alone versus 49% with annuloplasty. Mor-
tality occurred in 38% versus 48% of patients in
the medical versus surgical groups, respectively.
Unfortunately, quality of life and functional outcome
measures were not assessed.
Recurrent MR is frequent after MV annuloplasty for
secondary MR. Despite its initial abolition in nearly
all patients, moderate or greater MR recurs in 15% to
25% of patients at 6 to 12 months, increasing tow70%
at 5 years (55). Risk factors for MR recurrence include
more severe pre-operative MR, centrally directed or
multiple jets, greater degree of LV dilation, symmet-
ric anterior leaﬂet tethering, presence of a basal
aneurysm/dyskinesis, $11 mm coaptation height, and
a posterior leaﬂet angle of >45 (56). Recurrent MR
is also more frequent with use of partial bands or
ﬂexible complete rings (57–59), although recurrence
rates remain high even with complete rigid rings (60).
The current standard repair uses a complete rigid
ring, most commonly 28 mm in men and 26 mm in
women. Various ring designs have been developed,
including 1 speciﬁcally for ischemic MR, which
overcorrects for the increased tethering of the P3
segment (61). In patients with severe tethering,
chordal-sparing replacement may be preferable to
annuloplasty due to less frequent MR recurrence,
as discussed in the following text.
STUDIES IN NONISCHEMIC MR. In 54 patients with
dilated cardiomyopathy at a single center, secondary
MR was treated primarily with undersized annulo-
plasty rings with or without concomitant edge-
to-edge repair (57). At 5-year follow-up, 30% of
patients had died, and moderate/severe MR had
recurred in 19%. In the ACORN trial, 193 patients with
predominately nonischemic MR underwent MV sur-
gery (84% with an annuloplasty ring) with or without
placement of the CorCap LV restraint device (Acorn
Cardiovascular, St. Paul, Minnesota). ACORN patients
were younger and more often female than in most
surgical series of secondary MR, and 30-day mortality
was only 1.6% (62). However, during 5-year follow-
up, 30% of patients died, 15% had recurrent MR,
and 5% underwent repeat MV surgery (63). Additional
studies are required before surgery can routinely
be recommended for secondary MR in nonischemic
cardiomyopathy.
TABLE 3 Selected 1-Year Outcomes of MV Repair Versus Replacement for
Severe Ischemic MR (From the Cardiothoracic Surgical Trials Network)
MV Repair
(n ¼ 126)
MV Replacement
(n ¼ 125) p Value
LVESVI (ml/m2; primary endpoint) 54.6  25.0 60.7  31.5 0.18*
Recurrent moderate/severe MR 32.6% 2.3% <0.001
Moderate 28.4% 2.3% —
Severe 4.2% 0% —
Death 14.3% 17.6% 0.45
MV reoperation 2.4% 0% 0.25
Major adverse cardiac events† 32.5% 33.6% 0.86
New York Heart Association
functional class III/IV
9.0% 14.0% 0.28
Minnesota Living With
Heart Failure score
24.5  23.1 19.6  19.4 0.12
Values are mean  SD or %. *Adjusted for death. †Death, stroke, New York Heart Association
functional class increase by $1 grade, heart failure rehospitalization, or mitral valve reoperation.
Adapted with permission from Acker et al. (60).
LVESVI ¼ left ventricular end-systolic volume index; MV ¼ mitral valve.
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1239MV ANNULOPLASTY VERSUS REPLACEMENT. MV
replacement was used initially for secondary MR, but
was quickly abandoned due to frequent ventricular
decompensation. LV dysfunction in this setting was
due to early techniques including excision of the
mitral leaﬂets and subvalvular apparatus, resulting
in annular-ventricular discontinuity. Current valve-
sparing MV replacement techniques, which leave
the leaﬂets and subvalvular apparatus intact, pre-
serve LV function. In general, valve-sparing MV
replacement is preferred in patients with the most
severe degrees of tethering, as determined by a
tenting height >11 mm, a posterior leaﬂet angle >45,
or a basal aneurysm or dyskinesis (64–69). Other sit-
uations in which replacement is preferred include:
ruptured papillary muscle (acute ischemic MR); pa-
tients in cardiogenic shock; complex MR leaks with
multiple jets; failure of an initial repair; and for
surgeons who do not do many repairs.
Clinical studies suggested that repair is associated
with lower perioperative mortality, whereas replace-
ment provides better long-term correction with a
lower risk of recurrence (an important consideration,
because MR recurrence predisposes to HF, atrial
ﬁbrillation, and readmission). This perceived tradeoff
between reduced operative morbidity and mortality
with repair versus better long-term correction of
ischemic MR with replacement has generated sub-
stantial variation in surgical practice for this high-
prevalence condition.
A meta-analysis of 9 retrospective, nonrandomized
studies from 2004 to 2009, comprising 1,730 total
patients, compared MV repair with replacement for
ischemic MR, with the majority of patients also un-
dergoing CABG (69). The OR for short-term mortality
with MV replacement versus repair was 2.67 (95% CI:
1.86 to 3.82), with a long-term mortality HR of 1.35
(95% CI: 1.13 to 1.62). A more recent single-center
nonrandomized series conﬁrmed this observation:
2.3% in-hospital mortality with MV repair versus
12.5% with replacement (p ¼ 0.03), a difference
maintained at a median 2.3-year follow-up (70). In
addition, those treated with MV repair (but not
replacement) experienced improved LV function with
reverse LV remodeling.
Some studies have suggested that MV replacement
with preservation of the subvalvular apparatus may
be associated with similar or even lower mortality
than repair in HF, especially in patients with severe
bileaﬂet tethering (posterior lateral angle >45),
complex jets, and/or severe LV dysfunction or
multiple comorbidities (67). Among 244 propensity-
matched patient pairs with ischemic MR under-
going CABG with either MV ring annuloplasty orreplacement (with either mechanical or bioprosthetic
valves) at 13 Italian centers between 1996 and 2011,
although the 8-year mortality rate was similar be-
tween the 2 groups, recurrent MR and MV reoperation
was 2.8-fold more common with repair (70).
The issue of repair versus replacement was
addressed in a recently reported National Institutes
of Health–sponsored trial from the Cardiothoracic
Surgical Trials Network (CTSN), in which 251 patients
with severe ischemic MR were randomized to un-
dergo either MV repair with an undersized rigid or
semirigid complete annuloplasty ring or chordal-
sparing MV replacement (60). As seen in Table 3,
there were no signiﬁcant differences in the 1-year
primary endpoint of LV end-systolic volume index
or mortality. However, recurrence of at least moder-
ate MR at 1 year was substantially greater with MV
repair compared with replacement (32.6% vs. 2.3%,
p < 0.001). The strongest predictor of MR recurrence
after repair was a basal aneurysm/dyskinesis at
baseline (present in 62.1% of patients with vs. 20.5%
without recurrence, p < 0.001) (71). Hence, MV
replacement should be strongly considered when an
inferobasal aneurysm is present.
OTHER SURGICAL PROCEDURES FOR SECONDARY MR.
Although MV annuloplasty and replacement are the
most common surgical procedures, a number of
other techniques have been employed with varying
degrees of success. In at least 2 series, cutting of the
2 critical secondary chords to the anterior leaﬂet
corrected secondary MR without signiﬁcant ven-
tricular decompensation (72,73). This technique is
most commonly employed in patients with severe
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1240tethering of the anterior leaﬂet by the secondary
chords (seagull deformity). The restriction of the
anterior leaﬂet can be relieved and coaptation
restored with the free margin of the leaﬂet left intact.
Kron et al. (74) described subvalvular repositioning
of the displaced posterior papillary muscle toward
the right, ﬁbrous trigone as an adjunct to annulo-
plasty when severe degrees of tethering are present.
Another technique employed restoration of both
papillary muscles from their apical and lateral
distracted position into a more physiological parallel
alignment, resulting in less leaﬂet tethering.
In patients with severe mitral annular calciﬁcation
in which the annulus has been rendered immobile,
annuloplasty will not be effective, and replacement
is often not feasible. In these patients, a free edge-
to-edge approximation with suture (Alﬁeri tech-
nique) can improve the degree of MR (75). Likewise,
in patients undergoing surgical aortic valve replace-
ment with concomitant moderate secondary MR, an
Alﬁeri suture can be placed through the LV outﬂow
track after the aortic valve has been excised.
VENTRICULAR APPROACHES TO SECONDARY MR.
Two investigational extracardiac devices, the CorCap
(Acorn Cardiovascular) and Coapsys (Myocor, Maple
Grove, Minnesota), have been used to reshape the LV,
which may secondarily reduce the degree of second-
ary MR (Figure 4). The CorCap is a passive external
LV mesh restraint intended to reduce wall stress (62).
In the 300-patient randomized ACORN trial, the Cor-
Cap reduced LV dimensions, but not MR severity
or mortality compared with control patients (63). The
Coapsys cardiac support device also reshapes the
ventricle by placing a tether between anteriorly
and posteriorly placed extracardiac pads, with some
correction of the mitral annulus in the septal lateral
dimension, thereby reducing secondary MR (76). The
randomized RESTOR-MV (Randomized Evaluation
of a Surgical Treatment for Off-Pump Repair of the
Mitral Valve) trial in patients undergoing CABG with
at least moderate secondary MR was terminated
prematurely. Analysis of available data in 165 patients
at mean 28-month follow-up showed a survival
advantage for those treated with CABG plus Coapsys
without MV repair compared with CABG plus selec-
tive MV repair (HR: 0.42 [95% CI: 0.20 to 0.87],
p ¼ 0.04). Although LV dimensions were reduced to
a greater degree with Coapsys, MR reduction was
greater with conventional MV repair (p < 0.0001).
MANAGEMENT OF SECONDARY MR DURING CABG.
Optimal management of concomitant secondary MR
in patients undergoing CABG is still uncertain.
There is general agreement that severe MR shouldbe addressed at the time of CABG, because coronary
revascularization alone will only occasionally ame-
liorate MR (77,78). In the RIME (Randomised Ischae-
mic Mitral Evaluation) trial, 73 patients with
moderate secondary MR were randomized to CABG
plus MV annuloplasty versus CABG alone (79).
MV repair prolonged the duration of aortic cross-
clamping, cardiopulmonary bypass, intubation, and
hospitalization, and led to more blood transfusions,
although operative mortality was 3% in both groups.
At 1 year, MV annuloplasty resulted in improved
peak oxygen consumption during exercise (the pri-
mary endpoint), LV remodeling, and reduced MR
severity (80).
Several retrospective nonrandomized studies have
failed to demonstrate a survival beneﬁt of MV repair
in patients undergoing CABG for ischemic heart
disease with coexisting secondary MR (81,82). Con-
versely, in the prospective STICH (Surgical Treatment
of Ischemic Heart Failure) trial, 220 patients had site-
reported moderate/severe MR. Of 104 such patients
assigned to CABG, MV repair was performed at oper-
ator discretion in 49, whereas 116 were assigned to
medical therapy only (83). The 5-year adjusted HR
for mortality in patients with MR treated with CABG
plus MV repair versus medical therapy alone (without
CABG) was 0.41 (95% CI: 0.22 to 0.77, p ¼ 0.006),
whereas no survival advantage was evident with
CABG alone versus medical therapy. Thus, although
surgical correction of severe MR in patients under-
going CABG is generally recommended to improve
quality of life, in the absence of a large-scale ran-
domized trial, it is uncertain whether survival is
improved by mitral repair or replacement in this
setting. The recent American College of Cardiology
(ACC)/American Heart Association (AHA) guidelines
for the management of valvular heart disease give
MV surgery for secondary MR in the setting of CABG
a Class IIa indication (Level of Evidence [LOE]: C),
noting that addressing the MV at the time of surgery
is reasonable to avoid leaving the patient with se-
vere MR, despite the absence of conclusive evidence
that this approach prolongs life or ameliorates
symptoms (19).
The management of moderate MR in patients un-
dergoing cardiac surgery has been controversial. In
a recently reported National Institutes of Health–
sponsored randomized trial from the CTSN, 301
patients with moderate ischemic MR undergoing
CABG were randomized to coronary revascularization
alone versus coronary revascularization plus MV
annuloplasty with an undersized rigid annuloplasty
ring (84). The addition of annuloplasty resulted
in a longer duration of aortic cross clamping and
FIGURE 4 Extracardiac Devices Used to Remodel the Left Ventricle, Which May
Reduce Secondary Mitral Regurgitation
CorCap device Coapsys implant
Right 
ventricle
Anterior
pad
Mitral valve
Posterior
pad
Sub–valvular
chord
Left
ventricle
(Left) The CorCap cardiac support device is a passive external mesh restraint that directly
reduces the left ventricular end-diastolic dimension and wall stress. (Right) The Coapsys
device consists of a single-headed anterior pad and a dual-headed posterior pad connected
by a ﬂexible cord that reduces the left ventricular end-diastolic and end-systolic
dimension.
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1241cardiopulmonary bypass, and a longer hospital stay.
Annuloplasty did result in a reduction in the prev-
alence of moderate or severe MR at 1 year (11.2% vs.
31.0%, p < 0.001), but no signiﬁcant improvement in
LV systolic volume index, the primary endpoint
of the trial (p ¼ 0.61). There were also no signi-
ﬁcant between-group differences in deaths, read-
missions, functional status, or quality of life at
1 year, although the annuloplasty group had a higher
1-year rate of neurological events (9.6% vs. 3.1%, p ¼
0.03). Thus, although longer-term follow-up is
required to determine whether there is late beneﬁt
from the observed difference in MR at 1 year, ring
annuloplasty of moderate ischemic MR cannot be
routinely recommended in patients undergoing
CABG at this time.
CURRENT GUIDELINES FOR MV SURGERY IN
SECONDARY MR. The 2014 ACC/AHA valvular heart
disease guidelines contain 3 recommendations for
surgery in secondary MR (19). The ﬁrst states that MV
surgery is reasonable for patients with chronic, se-
vere secondary MR (stages C and D) undergoing CABG
or aortic valve replacement (Class IIa, LOE: C). The
second states that MV repair may be considered for
patients with chronic moderate secondary MR (stage
B) undergoing other cardiac surgery (Class IIb, LOE:
C). This latter recommendation was reached prior
to the negative results of the randomized moderate
ischemic MR trial being known (84). The third re-
commendation states that isolated MV surgery may
be considered for severely symptomatic patients
(NYHA functional class III to IV) with chronic severe
secondary MR (stage D) who have persistent symp-
toms despite optimal GDMT for HF (Class IIb, LOE: B).
Similarly, the most recent European guidelines (2012)
give a Class IIb (LOE: C) recommendation for MV
repair for isolated severe secondary MR, but only for
patients at low surgical risk with LVEF $30% (23).
TRANSCATHETER DEVICES FOR SECONDARY MR
Despite the poor prognosis with GDMT, most HF pa-
tients with secondary MR do not undergo MV surgery.
Between 2000 and 2008 at the Cleveland Clinic, only
36% of 814 patients with 3þ/4þ secondary MR un-
derwent MV surgery, and secondary MR comprised
90% of all nonoperated patients with severe MR (85).
Given the uncertain risk–beneﬁt ratio, MV surgery
is uncommon in patients not requiring CABG. As a
result, lesser-invasive transcatheter technologies
have been developed to treat secondary MR. These
devices are designed to imitate surgical approaches
that have proven to be successful in acutely reducing
MR, and may be classiﬁed according to whether theyperform direct or indirect annuloplasty, edge-to-edge
repair, chordal plication or replacement, complete
MV replacement, or other approaches (86). The pre-
sent review is restricted to the MitraClip, the only
device in widespread use (>15,000 implants to date)
and with sufﬁcient outcomes data to provide
comment.
THE MITRACLIP DEVICE. The MitraClip is a
polyester-covered cobalt-chromium clip inserted via
the femoral vein and advanced under trans-
esophageal echocardiographic guidance into the LA
following trans-septal puncture (Figure 5). The clip is
opened, positioned above the regurgitant jet, and
advanced into the LV. It is then retracted to grasp the
free edges of the mitral leaﬂets, the grippers are
dropped, and the clip is closed and released,
emulating a surgical edge-to-edge repair (Figure 6)
(87). Multiple clips may be safely placed, if necessary.
The MitraClip has CE mark approval for general use,
and Food and Drug Administration approval in the
United States for treatment of symptomatic patients
with severe primary MR at prohibitive risk for MV
surgery, although not for secondary MR.
In the EVEREST II (Endovascular Valve Edge-
to-Edge REpair Study), 278 relatively low-risk pa-
tients with 3þ/4þ MR were randomized to the
MitraClip or surgical MV repair. Compared with MV
surgery, the MitraClip was substantially safer, but
not as effective in reducing MR and LV remodeling
(88). Moreover, reﬂecting the early learning curve
FIGURE 5 The MitraClip Device
Close-up views of the MitraClip device’s fabric-covered clip (left) and guiding catheter
with clip delivery system (right). Images courtesy of Abbott Vascular, Menlo Park,
California.
FIGURE 6 Patholo
(Left) Double oriﬁce
severe secondary MR
arrow denotes tissue
Privitera et al. (87).
oriﬁce mitral valve w
Frederick St. Goar.
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1242with this device, acute procedural success (MR #2þ at
discharge) was achieved in only 77% of patients, and
21% required MV surgery. Nonetheless, with follow-
up to 4 years, NYHA functional class and overall
survival were similar in the 2 groups (89). Of note,
73% of the patients had primary MR, and only 27%
had secondary MR. A signiﬁcant interaction was
present between the randomized therapy and the
primary composite endpoint of death, MV surgery, or
3þ/4þ MR at both 1 and 4 years according to MR eti-
ology; patients with primary MR had signiﬁcantly
improved results with surgical MV repair, whereas
outcomes were at least as good with the MitraClip
in patients with secondary MR (Central Illustration)
(88,89).
Since device approval in Europe, the MitraClip
has been used extensively in patients at high risk orgical Changes After Edge-to-Edge Repairs
appearance 4 years after a surgical Alﬁeri repair for a patient with
due to ischemic cardiomyopathy. A indicates the anterior leaﬂet. The
growth over the suture site. Reproduced with permission from
(Right) Pathological appearance 6 months after creation of a double
ith the MitraClip. MR ¼ mitral regurgitation. Image courtesy ofcontraindicated for MV surgery, most commonly for
secondary MR. Numerous registries have demon-
strated high rates of procedural success and favorable
short-term outcomes (Table 4) (90–103). The TRAMI
(Transcatheter Mitral Valve Interventions) study is
the largest published registry to date (90). Among
1,064 patients treated with the MitraClip at 20
German centers, the median age was 75 years; 87%
had NYHA functional class III/IV HF symptoms; 69%
had LVEF <50%; secondary MR was present in 71%
of patients; and the median Society of Thoracic
Surgeons mortality score was 10. Procedural success
was achieved in 95% of patients, with no procedural
deaths. At w3-month follow-up, 12% of patients had
died and 12% had been hospitalized for HF, although
66% remained in NYHA functional class I/II. In the
ACCESS-EU (MitraClip Therapy Economic and Clinical
Outcomes Study Europe) registry, the MitraClip was
implanted in 567 patients at 14 sites between April
2009 and April 2011 (91). The mean logistic Euro-
SCORE was 23, and 77% of patients had secondary
MR. The clip implant rate was 99.6%, with multiple
clips used in 40% of patients. MR was reduced
to #2þ in 91% of patients, and there were 0 proce-
dural deaths. NYHA functional class and 6-min walk
distance substantially improved at 1-year follow-up.
Similarly, in the 25-center, 8-country, 2011 to
2012 European Sentinel Pilot Registry, 72% of 628
MitraClip-treated patients had secondary MR, 86%
had NYHA functional class III/IV symptoms, and the
mean EuroSCORE was 20.4 (92). Acute procedural
success was high (95.4%), with multiple clips used
in 39% of patients. In-hospital (2.9%) and 1-year
(15.3%) mortality were similar in patients with sec-
ondary and primary MR, although rehospitalization
for HF was more common in the secondary MR group
(25.8% vs. 12.0%, p ¼ 0.009). At 1 year, severe MR
was present in only 6% of patients. Pooled data
from the EVEREST II High-Risk Registry and U.S.
REALISM (Real World Expanded Multi-center Study
of the MitraClip System) registry were recently pub-
lished in which the MitraClip was used in 351 patients
with a Society of Thoracic Surgeons score or surgeon-
predicted operative mortality of $12% (70% of whom
had secondary MR) (93). By paired echocardiographic
core laboratory analysis, MR was #2þ in 89.7% of
patients at discharge and in 83.4% of patients at
1 year. Mortality was 4.8% at 30 days and 22.8% at
1 year. LV end-diastolic and end-systolic dimensions
decreased through 1-year follow-up, the physical and
mental components of the Short Form-36 quality-
of-life score improved, and the proportion of patients
with NYHA functional class III/IV symptoms was
reduced from 82.1% at baseline to 17.1% at 1 year.
CENTRAL ILLUSTRATION Secondary MR in Heart Failure: Interaction Between the Etiology of MR and the
Relative Success Rates of MV Surgery and MitraClip in the Randomized EVEREST II Trial
Success was deﬁned as freedom from the combined outcome of death, MV surgery, or reoperation, or MR >2þ (echocardiographic core laboratory
determination). Adapted with permission from Feldman et al. (88) and Mauri et al. (89). EVEREST II ¼ Endovascular Valve Edge-to-Edge REpair Study;
MR ¼ mitral regurgitation; MV ¼ mitral valve.
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1243The rate of hospitalizations for HF was signiﬁcantly
reduced in the year after MitraClip insertion,
compared with the year before (median per patient
0.41 vs. 0.79, p < 0.0001). All outcomes were direc-
tionally consistent in patients with secondary and
primary MR. The MitraClip has also been used suc-
cessfully in HF patients who are nonresponders to
CRT (an especially high-risk group), with resultant
improvements in MR grade, functional capacity, and
LV remodeling (104).
In a retrospective study, investigators in Italy
compared the outcomes of 91 patients with 3þ/4þ
secondary MR undergoing surgical MV repair be-
tween 2001 and 2011 with those of 52 patients
treated with MitraClip between 2008 and 2011.The MitraClip cohort was signiﬁcantly older, and
had more diabetes and chronic kidney disease,
higher logistic EuroSCOREs, lower LVEFs, and more
comorbidities. Conversely, 35% of the surgical MV
repair patients also underwent CABG (and other
cardiac procedures). MitraClip-treated patients had
signiﬁcantly lower rates of hospital mortality and
major infections, and a shorter length of stay
compared with surgical patients, although MR was
reduced to a lesser degree. Survival in the 2 groups
was similar at 1 year (105). In contrast, comparable
in-hospital and 6-month results were reported from
a retrospective comparison of 171 patients with
secondary MR treated with either the MitraClip
(n ¼ 95) or isolated MV repair (n ¼ 76) from the
TABLE 4 Large-Scale Published Registries of the MitraClip: Baseline Characteristics and Acute Procedural Success
Registry (Ref. #) N
Mean Age
(yrs) Male
Mean or
Median Risk
NYHA
Functional
Class III/IV
Mean
LVEF
FMR
Etiology
#2þ MR
Post
Multiple
Clips
Procedural
Success*
TRAMI (90) 1,064 75 62% 10%† 87% ‡ 71% 96% 1.5 mean 95%
ACCESS-EU (91) 567 78 64% 23%§ 85% k 77% 91% 40% 99.6%
European Sentinel (92) 628 74 63% 20%§ 86% 43% 72% 98% 37% 95%
EVEREST II and REALISM (93) 351 76 61% 11%† 85% 48% 70% 86% 39% —
GRASP (94) 171 71 62% 7%† 81% 37% 78% 93% 41% 99%
MARS (95) 142 71 64% 17%§ 68% 47% 54% 77% 47% 94%
Taramasso et al. (96) 109 69 84% 22%§ 82% 28% 100% 87% 65% 99%
MitraSwiss (97) 100 77 67% 17%§ 82% 48% 62% 85% 40% 85%
French multicenter (98) 62 73 72% 19%§ 81% 40% 74% 88% 17% 95%
Treede et al. (99) 202 75 63% 44%§ 98% 44% 65% 92% 35% 92%
Bozdag-Turan et al. (100) 121 77 69% 11%† 96% 42% 59% 99% 28% 97%
Rudolph et al. (101) 104 74 62% 36%§ 100% 43% 66% 92% 38% 92%
Braun et al. (102) 119 71 67% 28%§¶ 86% 35%‡ 35%¶ - - 86%
Neuss et al. (103) 157 74 67% 22%§ 100% 41% 73% 100% 16% 98%
*According to the registry protocol deﬁnition, which varied per study. †By Society for Thoracic Surgery score. ‡LVEF #50% in 69% of patients. §By the logistic EuroSCORE.
kLVEF #40% in 53% of patients. ¶In patients with FMR.
ACCESS-EU ¼ MitraClip Therapy Economic and Clinical Outcomes Study Europe; EVEREST II ¼ Endovascular Valve Edge-to-Edge REpair STudy; FMR ¼ functional mitral
regurgitation; GRASP ¼ Getting Reduction of Mitral Insufﬁciency by Percutaneous Clip Implantation; LVEF ¼ left ventricular ejection fraction; MARS ¼ MitraClip Asia-Paciﬁc
Registry; MR ¼mitral regurgitation; NYHA ¼ New York Heart Association; REALISM ¼ Real World Expanded Multi-center Study of the MitraClip System; TRAMI ¼ Transcatheter
Mitral Valve Interventions.
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1244University of Hamburg (106). Differences in baseline
characteristics and procedures between treated
groups in these studies emphasize the challenges
in interpreting the results of nonrandomized
comparisons.TABLE 5 Comparison of Ongoing Randomized Trials of the MitraClip
COAPT
Number of patients and sites 430 patients at 75 U.S. and Canadian site
Secondary MR grade (core
laboratory veriﬁed)
$3þ (EROA $30 mm2 and/or
Rvol >45 ml)
NYHA functional class II, III, or ambulatory IV
LVEF $20% to #50%
Surgical criteria Not appropriate for mitral valve
surgery (heart team)
Left ventricular volume
entry criterion
LV end-systolic dimension #70 mm
Control arm Guideline-directed medical therapy
(þCRT, if indicated)
Primary efﬁcacy endpoint
(superiority)
Heart failure rehospitalizations at 1 yr
Primary safety endpoint
(noninferiority)
The composite of: SLDA; device
embolization; endocarditis requiring
surgery; echocardiography core
laboratory-conﬁrmed mitral stenosis
requiring surgery; LVAD implant; heart
transplant; or any device-related
complications requiring nonelective
cardiovascular surgery at 12 months
Health economics Assessed
Follow-up, yrs 5
COAPT ¼ Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
regurgitant oriﬁce area; LV ¼ left ventricular; LVAD ¼ left ventricular assist device; MIT
Patients With Severe Secondary Mitral Regurgitation; Rvol ¼ regurgitant volume; RESH
Clinically Signiﬁcant Functional Mitral Regurgitation; SLDA ¼ single leaﬂet device attachCURRENT GUIDELINES FOR TRANSCATHETER DEVICE
USE IN SECONDARY MR. The 2012 European Society of
Cardiology/European Association for Cardio-Thoracic
Surgery valve and HF guidelines provide a Class IIb
(LOE: C) recommendation to consider MitraClip usein Patients With Heart Failure and Secondary Mitral Regurgitation
RESHAPE-HF MITRA-FR
s 800 patients at 50 E.U. sites 288 patients at 18 French sites
$3þ (EROA $30 mm2 and/or
Rvol >45 ml)
Severe (EROA >20 mm2 þ
Rvol >30 ml)
III or ambulatory IV II–IV
$15% to #40% $15% to #40%
None None
LV end-diastolic dimension
$55 mm
None
Guideline-directed medical
therapy (þCRT, if indicated)
Guideline-directed medical
therapy (þCRT, if indicated)
Death or heart failure
hospitalization at 1 yr
Death or recurrent heart failure
hospitalization at 1 yr
None None
Assessed None
2 2
for Heart Failure Patients with Functional Mitral Regurgitation; EROA ¼ effective
RA-FR ¼ Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in
APE-HF ¼ Randomized Study of the MitraClip Device in Heart Failure Patients With
ment; other abbreviations as in Table 4.
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MR, despite GDMT and CRT, who are inoperable or at
high risk (23). The 2013 ACCF/AHA HF guidelines
provide a Class IIb (LOE: B) recommendation to
consider MitraClip in symptomatic patients with
severe secondary MR despite GDMT after “careful
candidate selection” (43). Transcatheter MV repair
for secondary MR did not receive an ofﬁcial recom-
mendation in the 2014 ACCF/AHA valvular heart
disease guidelines, although it is recommended with
Class IIb (LOE: B) guidance for severe primary MR
in symptomatic patients at prohibitive risk for
MV surgery (19).
ONGOING TRIALS. Three large-scale trials are
randomizing symptomatic HF patients with 3þ/4þ
secondary MR to the MitraClip plus GDMT versus
GDMT alone (Table 5). The results of these trials will
clarify the role of the MitraClip in secondary MR, as
well as whether a therapy purely aimed at reducing
secondary MR improves prognosis in patients with
LV dysfunction as the primary pathophysiologic
disturbance.
CONCLUSIONS
The development of secondary MR is strongly asso-
ciated with a worsened prognosis in patients with
HF, regardless of its etiology. Accurate assessmentof MR severity in such patients can be challenging,
but is essential to help deﬁne patient risk and guide
treatment decisions. GDMT for HF is foundation
therapy for moderate and severe secondary MR,
along with CRT and coronary revascularization if
indicated. When effectively applied, these measures
will often reduce secondary MR and improve pa-
tient prognosis. The appropriate role of surgical and
transcatheter interventions for persistent severe
secondary MR is less clear and is evolving; both
options may be considered in carefully selected
patients after balancing the likely risks and bene-
ﬁts. Adequately designed randomized trials are
essential to further guide optimal use of these
invasive strategies, and several such trials with
the MitraClip are ongoing. Collaboration among
HF specialists, interventional cardiologists, car-
diac surgeons, and imaging experts as a multi-
disciplinary heart team is imperative to reach
consensus on appropriate care for patients with
secondary MR.
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